Gardasil
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cervical Intraepithelial Neoplasia
Conditions
Cervical Intraepithelial Neoplasia, Cervical Cancer, Cervical Neoplasm, Cervical Dysplasia, Human Papillomavirus
Trial Timeline
May 1, 2011 → Apr 1, 2012
NCT ID
NCT01338051About Gardasil
Gardasil is a phase 1 stage product being developed by Merck for Cervical Intraepithelial Neoplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT01338051. Target conditions include Cervical Intraepithelial Neoplasia, Cervical Cancer, Cervical Neoplasm.
What happened to similar drugs?
8 of 20 similar drugs in Cervical Intraepithelial Neoplasia were approved
Approved (8) Terminated (0) Active (12)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04022148 | Pre-clinical | UNKNOWN |
| NCT01432574 | Phase 2 | Completed |
| NCT01741012 | Phase 1 | Completed |
| NCT01338051 | Phase 1 | Completed |
| NCT00925288 | Approved | Completed |
| NCT01133509 | Pre-clinical | UNKNOWN |
| NCT00786409 | Pre-clinical | Completed |
| NCT00666107 | Pre-clinical | UNKNOWN |
Competing Products
20 competing products in Cervical Intraepithelial Neoplasia